H. Lundbeck A/S (HLUN-A.CO) Stock

HLUN-A.CO logo

H. Lundbeck A/S

HLUN-A.CODenmark
Healthcare

Company profile

H. Lundbeck A/S reported revenue of 24.63 billion DKK for fiscal year 2025, up 11.9% from fiscal year 2024, and net income of 3.19 billion DKK. That is a net profit margin of 13.0% for fiscal year 2025. Our analysis of its filings shows revenue growing from 19.91 billion DKK in fiscal year 2023 to 24.63 billion DKK in fiscal year 2025, 11.2% a year on average. H. Lundbeck A/S reports about 5,000 full-time employees.

What stands out

  • Revenue and net income in fiscal year 2025 were the highest of the last 5 fiscal years.

Figures from company filings; latest fiscal year ended December 31, 2025.

About H. Lundbeck A/S

H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression. It also provides Northera for symptomatic neurogenic orthostatic hypotension; Onfi for epilepsy; Sabril for refractory complex partial seizures and infantile spasms; Ebixa for dementia, Azilect for Parkinson's disease; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol for psychosis. In addition, the company develops Eptinezumab for migraine prevention; Eptinezumab, which is in phase 3 clinical trial for cluster headache; Lu AG09222, which is in phase 2 clinical trial for migraine prevention; Lu AG13909 that is in phase 1 clinical trial for neurohormonal dysfunctions; Brexpiprazole for post-traumatic stress disorder; Lu AF28996, which is in phase 1 clinical trial for Parkinson's disease; MAGLi program that is in phase 1 clinical trial for neurology; Bexicaserin, which is in phase 3 clinical trial for developmental and epileptic encephalopathies; Amlenetug that is in phase 3 clinical trial for synucleinopathies; and Lu AG22515, which is in clinical phase 1 clinical trial for neurology. Lundbeck A/S has a strategic research collaboration with Contera Pharma to develop oligonucleotide-based medicines for patients living with serious neurological conditions. The company was founded in 1915 and is headquartered in Valby, Denmark.

Leadership

  • Charl van Zyl — President & CEO, 58
  • Joerg Hornstein — CFO & Executive VP of Corporate Functions, 48
  • Tarek Samad Ph.D. — Executive VP and Head of Research & Development
  • Dianne Holto — Executive Vice President of People, Culture & Sustainability, 52
  • Thomas E. Gibbs — Executive VP & Head of Lundbeck in United States, 54

How much revenue does H. Lundbeck A/S make?

H. Lundbeck A/S reported 24.63 billion DKK in revenue for fiscal year 2025, up 11.9% from 22.00 billion DKK in fiscal year 2024.

How has H. Lundbeck A/S's revenue changed over the last 5 fiscal years?

Revenue by fiscal year: FY2021, 16.30 billion DKK; FY2022, 18.25 billion DKK; FY2023, 19.91 billion DKK; FY2024, 22.00 billion DKK; FY2025, 24.63 billion DKK.

Company Information

SectorHealthcare
IndustryBrain and Nerve Treatment Drugs
Employees5,000
HeadquartersValby, Denmark
ExchangeCopenhagen
TimezoneEurope/Copenhagen (CET)

Contact & Links

Address
Ottiliavej 9, Valby, 2500
Phone
45 36 30 13 11
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.

Data as of .

How to cite: DataPorium, “H. Lundbeck A/S (HLUN-A.CO)”, data as of Dec 31, 2025, https://dataporium.tech/stocks/HLUN-A.CO

LinkedInLinkedInXXYouTubeYouTube